DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Central Nervous System Disorders Therapeutics Market 2016-2020" report to their offering.
The report forecasts the global central nervous system (CNS) disorders therapeutics market to grow at a CAGR of 3.38% during the period 2016-2020.
The report covers the present scenario and the growth prospects of the global central nervous system (CNS) disorders therapeutics market for 2016-2020.
To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-labeled drugs used for the treatment of various CNS disorders including bipolar disorders, depression, epilepsy, PD, AD, Huntington's disease (HD), multiple sclerosis (MS), schizophrenia, attention-deficit hyperactivity disorder (ADHD), migraine, and anxiety.
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Companies Mentioned Include:
- Eli Lilly
- Abital Pharma
- Aprecia Pharmaceuticals
- Archer Pharmaceuticals
- MSI Methylation Sciences
- Opko Health
- Par Pharmaceuticals
- SAGE Therapeutics
- US WorldMeds
- Valeant Pharmaceuticals
- Zinfandel Pharmaceuticals
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Pipeline portfolio
PART 06: Market landscape
PART 07: Market segmentation by type of disease
PART 08: Geographical segmentation
PART 09: Market drivers
PART 10: Impact of drivers
PART 11: Market challenges
PART 12: Impact of drivers and challenges
PART 13: Market trends
PART 14: Vendor landscape
PART 15: Appendix
PART 16: About the Author
For more information about this report visit http://www.researchandmarkets.com/research/4vx2r6/global_central